Rhythm Biosciences Limited

Equities

RHY

AU000000RHY2

Biotechnology & Medical Research

Market Closed - Australian S.E. 02:11:03 2024-06-07 am EDT 5-day change 1st Jan Change
0.07 AUD 0.00% Intraday chart for Rhythm Biosciences Limited -1.41% -48.15%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Rhythm Biosciences' Buttula to Revert to Nonexecutive Chair Role; Shares Up 3% MT
Rhythm Biosciences Appoints CEO; Shares Down 3% MT
Rhythm Biosciences Receives AU$2.5 Million Under Rights Issue; Shares Up 3% MT
Rhythm Biosciences Limited(ASX:RHY) dropped from S&P/ASX All Ordinaries Index CI
Rhythm Biosciences Limited(ASX:RHY) dropped from S&P/ASX Emerging Companies Index CI
Rhythm Biosciences Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Rhythm Biosciences Seeks to Raise AU$6.6 Million Via Rights Offer; Shares Fall 29% MT
Rhythm Biosciences Limited Announces Resignation of Rachel David as Non-Executive Director CI
Rhythm Biosciences Ltd Announces the Appointment of James Barrie as Joint Company Secretary, Effective 1 January 2024 CI
Rhythm Biosciences Identifies Lung Cancer Biomarkers from Blood Samples; Shares Fall 6% MT
Rhythm Biosciences Limited Announces Resignation of Paul Smith as CFO CI
Rhythm Biosciences Limited Announces Executive Changes CI
Rhythm Biosciences Receives First Tranche of R&D Tax Rebate MT
Rhythm Biosciences' Breast Cancer Diagnostic Test Shows Positive Results MT
Rhythm Biosciences Joins Forces to Automate Cancer Test Kit MT
Rhythm Biosciences Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Rhythm Biosciences Appoints Director to Newly Created Deputy Chair Role MT
Rhythm Biosciences Signs Deal for UK Entry of Cancer Test MT
Rhythm Biosciences Secures UK Certification for Diagnostic Test; Shares Surge 89% MT
Rhythm Biosciences CEO Steps Down; Shares Slump 13% MT
Rhythm Biosciences Limited Announces Management Changes CI
Rhythm Biosciences Ltd Announces Executive Changes CI
Rhythm Biosciences Pulls Out TGA Submission for Colorectal Cancer Diagnostic Kit MT
Rhythm Biosciences Limited Provides Update to TGA Submission for ColoSTAT® Test-Kit CI
Rhythm Biosciences Shares Suspended from Australian Bourse MT
Chart Rhythm Biosciences Limited
More charts
Rhythm Biosciences Ltd is an Australia-based medical diagnostics company. The Company is engaged in delivering simple, affordable blood tests for accurate and early detection of cancers. It is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives. The Company has developed ColoSTAT, a blood test for the detection of Colorectal Cancer (CRC). If diagnosed early, colorectal cancer is curable. The ColoSTAT Test-Kit measures five specific protein biomarkers that indicate the likelihood of CRC. The test is an alternative for individuals who are unable or unwilling to participate in current screening programs. It is being updated to meet the IVDR (In vitro diagnostic medical devices regulation) regulatory standards. It is focused on working with likeminded global partners to achieve commercialization and distribution of these simple solutions.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. RHY Stock
  4. News Rhythm Biosciences Limited
  5. Rhythm Biosciences Chair Sells Shares to Domestic Fund Manager